FDA grants priority review to Merck’s sBLA for KEYTRUDA® for treatment of HNSCC
Merck announced the FDA has accepted a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of patients with recurrent or metastatic HNSCC. February 11, 2019